Results 41 to 50 of about 6,967 (165)

Cardiorenal syndrome [PDF]

, 2015
published_or_final_versio
Pai, MCP
core   +1 more source

Exposure to potentially teratogenic medications before and during the first trimester of pregnancy compared to women of childbearing age: A retrospective analysis of Swiss claims data (2015–2021)

Acta Obstetricia et Gynecologica Scandinavica, Volume 104, Issue 4, Page 707-719, April 2025.
In Switzerland, most dispensed medications with teratogenic effect debated or proven were in the group of weak teratogenicity level. Reassuringly, many women discontinue treatment with potential teratogens before pregnancy. Abstract Introduction Exposure to potentially teratogenic medications during pregnancy is underinvestigated in Switzerland.
Carole A. Marxer, Sereina M. Graber, Daniel Surbek, Alice Panchaud, Christoph R. Meier, Julia Spoendlin   +5 more
wiley   +1 more source

Review of Tolvaptan in the Treatment of Hyponatremia [PDF]

Clinical Medicine Insights: Therapeutics, 2011
Hyponatremia is a very common electrolyte disorder and is a significant independent predictor of medical prognosis and costs. Tolvaptan is a vasopressin receptor antagonist developed for the treatment of hyponatremia. It has its principal application in the treatment of euvolemic and hypervolemic hyponatremia.
Apurv Khanna, Amarinder Singh Garcha
openaire   +2 more sources

Automated Microfluidic Platform for High‐Throughput Biosensor Development

Advanced Sensor Research, Volume 4, Issue 3, March 2025.
Nanopore‐based biosensors are transformative for point‐of‐care diagnostics. This study introduces Bio‐Sensei, a high‐throughput microfluidic IoT platform integrating robotic sampling, electrochemical, and fluorescence setup. Functionalized with an ATCUN peptide for Cu2⁺ detection, it achieves LODs of 10⁻⁶ and 10⁻¹⁵ M in fluorescence and I–V ...
Shitanshu Devrani, Daniel Tietze, Alesia A. Tietze   +2 more
wiley   +1 more source

Terapia diuretica nell’insufficienza cardiaca cronica: evidenze, esperienze, prospettive = Diuretic treatment in patients with chronic heart failure: evidences, experiences, and current perspectives [PDF]

, 2017
Congestion is a fundamental clinical sign in patients with chronic heart failure (CHF). Diuretics are the mainstay treatment for congestion but, so far, no randomized trial has ever shown any beneficial effect of diuretics on mortality in patients with ...
Carubelli, Valentina, Pellicori, Pierpaolo   +1 more
core   +1 more source

Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches

PROTEOMICS, EarlyView.
Paul Perco, Matthias Ley, Kinga Kęska‐Izworska, Dorota Wojenska, Enrico Bono, Samuel M. Walter, Lucas Fillinger, Klaus Kratochwill   +7 more
wiley   +1 more source

Prognostic impact of being underweight in patients undergoing mitral TEER: The OCEAN‐Mitral registry

ESC Heart Failure, Volume 12, Issue 1, Page 408-417, February 2025.
Of the patients undergoing mitral transcatheter edge‐to‐edge repair, 20.9% were underweight, with a body mass index less than 18.5 kg/m2. Underweight patients had higher rates of all‐cause, cardiovascular, and non‐cardiovascular mortality, and being underweight was independently associated with all‐cause and cardiovascular mortality.
Ryosuke Higuchi, Masaki Izumo, Yuki Izumi, Mike Saji, Mitsuaki Isobe, Yoshihiro Akashi, Masanori Yamamoto, Masahiko Asami, Yusuke Enta, Masaki Nakashima, Shinichi Shirai, Shingo Mizuno, Yusuke Watanabe, Makoto Amaki, Kazuhisa Kodama, Junichi Yamaguchi, Toru Naganuma, Hiroki Bota, Yohei Ohno, Masahiro Yamawaki, Hiroshi Ueno, Kazuki Mizutani, Shunsuke Kubo, Toshiaki Otsuka, Kentaro Hayashida, on behalf of the OCEAN‐Mitral Investigators   +25 more
wiley   +1 more source

Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis

Internal Medicine, 2016
Objective Tolvaptan was first approved for use for cirrhosis in Japan in September 2013. The aim of the study was to examine the effect of tolvaptan, a vasopressin V2 receptor antagonist, on the prognosis of cirrhosis. Methods The effect of tolvaptan was evaluated in 26 patients with cirrhosis treated at our hospital from September 2013 to April 2015 ...
Taro Takami, Tsuyoshi Ishikawa, Takuya Iwamoto, Isao Sakaida, Masaki Maeda, Takuro Hisanaga, Koichi Fujisawa, Toshihiko Matsumoto, Issei Saeki, Isao Hidaka   +9 more
openaire   +4 more sources

Long‐term efficacy of SGLT2 inhibitors for elderly patients with acute decompensated heart failure: The OASIS‐HF study

ESC Heart Failure, Volume 12, Issue 1, Page 447-455, February 2025.
Abstract Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) have been widely demonstrated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization, regardless of left ventricular ejection fraction (LVEF). However, data on the extent to which rehospitalization is suppressed following HF hospitalization are limited.
Michitaka Amioka, Hiroki Kinoshita, Yuto Fuji, Kazuhiro Nitta, Kenichi Yamane, Tomoki Shokawa, Yukiko Nakano   +6 more
wiley   +1 more source

International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people [PDF]

, 2019
These recommendations were systematically developed on behalf of the Network for Early Onset Cystic Kidney Disease (NEOCYST) by an international group of experts in autosomal dominant polycystic kidney disease (ADPKD) from paediatric and adult nephrology,
Bergmann, Carsten, Bockenhauer, Detlef, Breysem, Luc, Cadnapaphornchai, Melissa A, Cetiner, Metin, Dudley, Jan, Emma, Francesco, Gimpel, Charlotte, Harris, Peter C, Harris, Tess, Konrad, Martin, König, Jens, Liebau, Max C, Marlais, Matko, Mekahli, Djalila, Metcalfe, Alison, Oh, Jun, Perrone, Ronald D, Schaefer, Franz, Sinha, Manish D, Titieni, Andrea, Torra, Roser, Weber, Stefanie, Winyard, Paul JD   +23 more
core   +2 more sources